Abstract:SESSION TITLE: Asthma IV SESSION TYPE: Original Investigation Poster PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM PURPOSE: Interleukin-33 (IL-33) dysregulation plays a critical role in the pathogenesis of asthma airway inflammation and remodeling. However, the cellular and molecular mechanisms of IL-33 in asthma remodeling remain unclear. METHODS: Expression of IL-33 and ST2 was examined in lung specimens from patients with asthma using immunohischemical analysis. Human lung fibroblasts were pretreated with anti-ST2 antibody, U0126 and H89 respectively and then treated with IL-33 recombination protein. Then western blot, cell immunofluorescence and real-time quantitative PCR were used to determine the activation of extracellular signal-regulated protein kinase 1/2 (ERK1/2) and mitogen- and stress-activated protein kinase 1 (MSK1) and the expression of alpha smooth muscle actin (α-SMA) and collagen I. In addition, the effect of soluble ST2 (sST2) was tested in a mouse asthma model to determine if IL-33 blocking influences airway remodeling of asthma. RESULTS: We found that expression of IL-33 and ST2 was upregulated in airway samples from patients with asthma. Furthermore, we showed in vitro that IL-33 induced α-SMA and collagen I expression via ST2-ERK1/2-MSK1 signaling pathway in human lung fibroblast. Using a mouse asthma model, we demonstrated that IL-33 neutralization by administration of sST2 inhibited IL-33/ST2-ERKI/2-MSK1signaling pathway and airway remodeling in vivo. CONCLUSIONS: In conclusion, these data indicate that IL-33, binding with its receptor ST2, can induce α-SMA and collagens I expression in human lung fibroblast through ERK1/2/MSK1 signaling pathway. CLINICAL IMPLICATIONS: IL-33 blocking by sST2 overcomes ovalbumin (OVA)-induced airway remodeling in vivo and may serve as a new therapeutic option for asthma. DISCLOSURE: The following authors have nothing to disclose: Liang Dong No Product/Research Disclosure Information

IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk

Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling

IL-33 amplifies airways inflammation in a murine surrogate of asthma possibly through acting on dendritic cells

IL-33 Promotes Airway Remodeling and is a Marker of Asthma Disease Severity

IL-33 Promotes Airway Remodeling in a Mouse Model of Asthma Via ERK1/2 Signaling Pathway

IL-33/ST2 axis deficiency exacerbates neutrophil-dominant allergic airway inflammation

IL-33 Induces Cellular and Exosomal miR-146a Expression as a Feedback Inhibitor of Mast Cell Function

Interleukin-17 Orchestrates the Granulocyte Influx into Airways after Allergen Inhalation in A Mouse Model of Allergic Asthma

Interleukin 31 receptor α promotes smooth muscle cell contraction and airway hyperresponsiveness in asthma

[IL-33/ST2 Promotes Airway Remodeling in Asthma by Activating the Expression of Fibronectin 1 and Type 1 Collagen in Human Lung Fibroblasts].

Endoplasmic reticulum stress drives macrophages to produce IL-33 to favor Th2 polarization in the airways

Regulation of IL (Interleukin)-33 Production in Endothelial Cells Via Kinase Activation and Fas/CD95 Upregulation

IL-27 Signaling Negatively Regulates FcɛRI-mediated Mast Cell Activation and Allergic Response

Effect of Interleukin-33 on Th1/Th2 Cytokine Ratio in Peripheral Lymphocytes in Asthmatic Mice.

Interleukin-33-activated basophils promote asthma by regulating Th2 cell entry into lung tissue

Lung Dysfunction in a Mouse Model of Inflammation is Dependent on T-cell-independent IL-13 Expression (54.18)

House dust mite exposure upregulates C3a receptor expression in pulmonary innate immune cells during the sensitization phase of allergic asthma by an IL-33-dependent mechanism

IL-4Rα signaling in CD4+CD25+FoxP3+ T regulatory cells restrains airway inflammation via limiting local tissue IL-33

IL-33 Promotes Airway Remodeling in Asthma Through ST2/ERK1/2/MSK1 Signal Pathway

Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD

IL-33 Exacerbates Antigen-Induced Arthritis by Activating Mast Cells